Amneal Pharmaceuticals Statistics
Total Valuation
AMRX has a market cap or net worth of $2.41 billion. The enterprise value is $4.98 billion.
Important Dates
The last earnings date was Friday, November 8, 2024, before market open.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
AMRX has 309.84 million shares outstanding. The number of shares has increased by 88.69% in one year.
Current Share Class | 309.84M |
Shares Outstanding | 309.84M |
Shares Change (YoY) | +88.69% |
Shares Change (QoQ) | -2.92% |
Owned by Insiders (%) | 51.60% |
Owned by Institutions (%) | 45.97% |
Float | 148.23M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 11.48 |
PS Ratio | 0.85 |
Forward PS | 0.84 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | 9.16 |
P/OCF Ratio | 7.71 |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 8.78, with an EV/FCF ratio of 18.92.
EV / Earnings | n/a |
EV / Sales | 1.86 |
EV / EBITDA | 8.78 |
EV / EBIT | 14.65 |
EV / FCF | 18.92 |
Financial Position
The company has a current ratio of 1.38
Current Ratio | 1.38 |
Quick Ratio | 0.79 |
Debt / Equity | n/a |
Debt / EBITDA | 4.50 |
Debt / FCF | 10.05 |
Interest Coverage | 1.32 |
Financial Efficiency
Return on equity (ROE) is -185.77% and return on invested capital (ROIC) is 7.57%.
Return on Equity (ROE) | -185.77% |
Return on Assets (ROA) | 5.94% |
Return on Capital (ROIC) | 7.57% |
Revenue Per Employee | $341,455 |
Profits Per Employee | -$23,497 |
Employee Count | 7,850 |
Asset Turnover | 0.75 |
Inventory Turnover | 2.90 |
Taxes
In the past 12 months, AMRX has paid $23.32 million in taxes.
Income Tax | 23.32M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +45.42% in the last 52 weeks. The beta is 1.10, so AMRX's price volatility has been similar to the market average.
Beta (5Y) | 1.10 |
52-Week Price Change | +45.42% |
50-Day Moving Average | 8.42 |
200-Day Moving Average | 7.39 |
Relative Strength Index (RSI) | 39.53 |
Average Volume (20 Days) | 1,183,361 |
Short Selling Information
The latest short interest is 4.67 million, so 1.51% of the outstanding shares have been sold short.
Short Interest | 4.67M |
Short Previous Month | 3.50M |
Short % of Shares Out | 1.51% |
Short % of Float | 3.15% |
Short Ratio (days to cover) | 4.02 |
Income Statement
In the last 12 months, AMRX had revenue of $2.68 billion and -$184.45 million in losses. Loss per share was -$0.63.
Revenue | 2.68B |
Gross Profit | 979.05M |
Operating Income | 339.77M |
Pretax Income | -157.04M |
Net Income | -184.45M |
EBITDA | 566.76M |
EBIT | 339.77M |
Loss Per Share | -$0.63 |
Full Income Statement Balance Sheet
The company has $77.26 million in cash and $2.64 billion in debt, giving a net cash position of -$2.57 billion or -$8.29 per share.
Cash & Cash Equivalents | 77.26M |
Total Debt | 2.64B |
Net Cash | -2.57B |
Net Cash Per Share | -$8.29 |
Equity (Book Value) | -33.68M |
Book Value Per Share | -0.30 |
Working Capital | 418.09M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $312.84 million and capital expenditures -$49.67 million, giving a free cash flow of $263.18 million.
Operating Cash Flow | 312.84M |
Capital Expenditures | -49.67M |
Free Cash Flow | 263.18M |
FCF Per Share | $0.85 |
Full Cash Flow Statement Margins
Gross margin is 36.53%, with operating and profit margins of 12.68% and -6.88%.
Gross Margin | 36.53% |
Operating Margin | 12.68% |
Pretax Margin | -4.59% |
Profit Margin | -6.88% |
EBITDA Margin | 21.14% |
EBIT Margin | 12.68% |
FCF Margin | 9.82% |
Dividends & Yields
AMRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -88.69% |
Shareholder Yield | -88.69% |
Earnings Yield | -7.65% |
FCF Yield | 10.92% |
Dividend Details Analyst Forecast
The average price target for AMRX is $10.00, which is 28.54% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $10.00 |
Price Target Difference | 28.54% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
AMRX has an Altman Z-Score of 1.32 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.32 |
Piotroski F-Score | 6 |